China National Pharmaceutical Group Corporation: Holding Subsidiary Drugs pass Generic Drug Consistency Evaluation.

The announcement of China National Pharmaceutical Group Corporation states that its controlling subsidiary, Shantou Jinshi Fine Injectable Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, approving the injection of cefoperazone sodium through generic drug quality and efficacy consistency evaluation. This drug is a third-generation cephalosporin, used for lower respiratory tract infections and urinary tract infections caused by sensitive bacteria. According to data from the PDB Drug Comprehensive Database, the total sales in all channels in China in 2024 are expected to reach 30.21 billion yuan. Currently, other companies that have passed the consistency evaluation for injection cefoperazone sodium include Hainan Lingkang Pharmaceutical Co., Ltd. and Zhejiang Asia-Pacific Pharmaceutical Co., Ltd.